Abstract
Corneal collagen cross-linking (CXL) entails the use of ultraviolet light with a cross-linking agent to form cross bridges in the corneal collagen fibers with subsequent strengthening of the corneal stroma. CXL was first reported on humans in 2003 for patients with keratoconus. Since then, the procedure showed promising results in post-LASIK ectasia. One of the new applications of CXL is in infectious keratitis. In this review, the authors discuss the applications of CXL and cover the new advances in this field. CXL is still not US FDA approved in the USA.